These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 38357542)
1. Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma. Rezagholizadeh F; Tajik F; Talebi M; Taha SR; Shariat Zadeh M; Farhangnia P; Hosseini HS; Nazari A; Mollazadeh Ghomi S; Kamrani Mousavi SM; Haeri Moghaddam N; Khorramdelazad H; Joghataei MT; Safari E Front Immunol; 2024; 15():1283364. PubMed ID: 38357542 [TBL] [Abstract][Full Text] [Related]
2. High-expression of V-domain Imuunoglobulin Suppressor of T-cell Activation (VISTA) Is Correlated with Advanced Pathological Features in Patients with Pancreatic Ductal Adenocarcinoma. Nickho H; Falak R; Rezagholizadeh F; Khoshmirsafa M; Joghataei MT; Mollazadeh Ghomi S; Safari E Iran J Allergy Asthma Immunol; 2024 May; 23(3):257-271. PubMed ID: 39422386 [TBL] [Abstract][Full Text] [Related]
3. Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. McGuigan AJ; Coleman HG; McCain RS; Kelly PJ; Johnston DI; Taylor MA; Turkington RC J Pathol Clin Res; 2021 Mar; 7(2):99-112. PubMed ID: 33481339 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Diana A; Wang LM; D'Costa Z; Allen P; Azad A; Silva MA; Soonawalla Z; Liu S; McKenna WG; Muschel RJ; Fokas E Oncotarget; 2016 Jul; 7(27):40992-41004. PubMed ID: 27329602 [TBL] [Abstract][Full Text] [Related]
5. Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer. Hou Z; Pan Y; Fei Q; Lin Y; Zhou Y; Liu Y; Guan H; Yu X; Lin X; Lu F; Huang H J Cancer Res Clin Oncol; 2021 Feb; 147(2):517-531. PubMed ID: 33237432 [TBL] [Abstract][Full Text] [Related]
6. Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival. Danilova L; Ho WJ; Zhu Q; Vithayathil T; De Jesus-Acosta A; Azad NS; Laheru DA; Fertig EJ; Anders R; Jaffee EM; Yarchoan M Cancer Immunol Res; 2019 Jun; 7(6):886-895. PubMed ID: 31043417 [TBL] [Abstract][Full Text] [Related]
7. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas. Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504 [TBL] [Abstract][Full Text] [Related]
8. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616 [TBL] [Abstract][Full Text] [Related]
10. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma. Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360 [TBL] [Abstract][Full Text] [Related]
11. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma. Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054 [TBL] [Abstract][Full Text] [Related]
12. Ubiquitin-Specific Protease 43 Impacts Pancreatic Ductal Adenocarcinoma Prognosis by Altering Its Proliferation and Infiltration of Surrounding Immune Cells. Zhao Z; Lin Z; Guo X; Al-Danakh A; He H; Qin H; Ma C; Zhang N; Tan G J Immunol Res; 2023; 2023():4311388. PubMed ID: 37050932 [TBL] [Abstract][Full Text] [Related]
13. Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Diana A; Wang LM; D'Costa Z; Azad A; Silva MA; Soonawalla Z; Allen P; Liu S; McKenna WG; Muschel RJ; Fokas E Oncotarget; 2016 Nov; 7(45):72819-72832. PubMed ID: 27637082 [TBL] [Abstract][Full Text] [Related]
14. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma. Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S Front Immunol; 2021; 12():648917. PubMed ID: 33777046 [No Abstract] [Full Text] [Related]
15. CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma. Yang G; Wang Y; Xiao J; Zhao F; Qiu J; Liu Y; Chen G; Cao Z; You L; Zheng L; Zhang T; Zhao Y Cell Oncol (Dordr); 2021 Apr; 44(2):345-355. PubMed ID: 33125631 [TBL] [Abstract][Full Text] [Related]
16. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma. Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231 [TBL] [Abstract][Full Text] [Related]
18. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma. Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420 [TBL] [Abstract][Full Text] [Related]
19. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. Chang DZ; Ma Y; Ji B; Liu Y; Hwu P; Abbruzzese JL; Logsdon C; Wang H J Hematol Oncol; 2012 Apr; 5():15. PubMed ID: 22475564 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of NEDD9, E-cadherin and γ-catenin and their prognostic significance in pancreatic ductal adenocarcinoma (PDAC). Radulović P; Krušlin B Bosn J Basic Med Sci; 2018 Aug; 18(3):246-251. PubMed ID: 29924959 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]